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ABSTRACT
Chronic myeloid leukemia (CML) is characterized by a genomic translocation 
generating a permanently active BCR-ABL oncogene with a complex pattern of 
atypically tyrosine-phosphorylated proteins that drive the malignant phenotype 
of CML. Recently, the LIM and SH3 domain protein 1 (LASP1) was identified as a 
component of a six gene signature that is strongly predictive for disease progression 
and relapse in CML patients. However, the underlying mechanisms why LASP1 
expression correlates with dismal outcome remained unresolved.
Here, we identified LASP1 as a novel and overexpressed direct substrate of 
BCR‑ABL in CML. We demonstrate that LASP1 is specifically phosphorylated by 
BCR-ABL at tyrosine-171 in CML patients, which is abolished by tyrosine kinase 
inhibitor therapy. Further studies revealed that LASP1 phosphorylation results 
in an association with CRKL ‑ another specific BCR‑ABL substrate and bona fide 
biomarker for BCR-ABL activity. pLASP1-Y171 binds to non-phosphorylated CRKL 
at its SH2 domain. Accordingly, the BCR-ABL-mediated pathophysiological hyper-
phosphorylation of LASP1 in CML disrupts normal regulation of CRKL and LASP1, 
which likely has implications on downstream BCR-ABL signaling. Collectively, our 
results suggest that LASP1 phosphorylation might serve as an additional candidate 
biomarker for assessment of BCR‑ABL activity and provide a first step toward a 
molecular understanding of LASP1 function in CML.
INTRODUCTION
Chronic myeloid leukemia (CML) is a hematopoietic 
stem cell disease, characterized by clonal expansion of 
differentiated cells. CML is driven by the Philadelphia 
(Ph) chromosome, which results in the generation of 
the BCR‑ABL fusion oncogene and expression of the 
constitutively active BCR‑ABL tyrosine kinase. As a 
consequence, the deregulated kinase phosphorylates 
substrates such as ERK and STAT5 and causes activation 
of RAS/MAPK/ERK downstream signaling and the 
PI3K/AKT pathway, which ultimately promotes cell 
proliferation and suppresses apoptosis [1, 2].
Abnormal integrin function is based on BCR‑ABL 
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phosphorylation of cytoskeleton proteins such as 
paxillin, talin, focal adhesion kinase 2 (FAK2), and 
CRKL (Crk‑like) [3, 4]. CRKL is an adaptor protein 
and the major substrate of BCR‑ABL in CML cells [5]. 
The phosphorylation status of CRKL has been used as a 
marker to predict the efficacy of tyrosine kinase inhibitors 
(TKI; e.g. imatinib and nilotinib) in the treatment of CML 
patients [6, 7]. In this context, we wondered whether other 
established physiological ABL kinase substrates are pre‑
phosphorylated in leukemia cells. A known substrate of 
ABL is the LIM and SH3 domain protein LASP1 [8]. 
Interestingly, Yeung et al. recently identified LASP1 as 
one out of six signature genes that are highly predictive 
for CML disease phases, which enable a more accurate 
prediction of relapse after stem cell transplantation than 
clinical risk factors alone [9].
LASP1 was initially identified from a cDNA 
library of breast cancer metastases and predominantly 
localizes at sites of actin assembly, such as focal contacts, 
lamellipodia and membrane ruffles [10, 11], where it 
interacts with a number of motility associated proteins 
such as zyxin, dynamin, lipoma preferred partner (LPP), 
actin, paladin and kelch related protein 1 (KRP1) [10]. 
Phosphorylation at Tyr‑171 by ABL is seen in apoptotic 
cells and specifically blocks LASP1 translocation to 
sites of focal adhesions, i.e. cell‑matrix and cell‑cell 
contacts [8]. Although LASP1 is expressed at low basal 
levels in virtually all normal human tissues [10], protein 
overexpression has been observed in several cancer 
entities e.g. breast, ovarian, colon, prostate, liver, and 
bladder carcinoma as well as medulloblastoma [12‑17]. 
Furthermore, LASP1 expression and nuclear localization 
significantly correlates with poor outcome of cancer 
patients [11, 12, 15, 18]. Silencing of LASP1 by RNA 
interference in various cell lines results in a strong 
inhibition of proliferation and migration with cell‑cycle 
arrest in G2/M phase, whereas overexpression increased 
cancer cell proliferation and cell motility [13, 19].
As the oncogenic BCR‑ABL tyrosine kinase 
is constitutively active, LASP1 may not only be 
phosphorylated in apoptotic cells, but also in defined Ph 
chromosome positive CML cells. Here, we integrated 
comprehensive transcriptomic and biochemical data 
demonstrating that LASP1 is highly overexpressed and 
specifically phosphorylated at tyrosine‑171 by BCR‑ABL 
in CML patients. Moreover, we identified LASP1 as 
a novel binding partner of CRKL and elucidated the 
mode of this protein‑protein‑interaction. Collectively, 
our results suggest that LASP1 phosphorylation might 
serve as a candidate biomarker for measurement of 
BCR‑ABL activity and point to an important role of 
LASP1 in aberrant BCR‑ABL signaling. Moreover, these 
data provide a first mechanistic insight in why LASP1 
overexpression might contribute to CML progression.
RESULTS
LASP1 is overexpressed in CML
Known to be overexpressed in several cancer 
entities [12‑16, 19], we sought to investigate the LASP1 
gene expression pattern in publicly available microarray 
datasets for leukemia and normal tissues. Specifically, 
microarray data of an established normal body atlas (n = 
353) [20] normal CD34+ HSCs (n = 35) [21], macrophages 
(n = 45), monocytes (n = 26), B cells (n = 24), and T 
cells (n = 20 ) were compared with those for four major 
lymphoma and leukemia entities (n = 819). As displayed 
in Figure 1A, LASP1 is significantly (p < 0.0001) and 
highly overexpressed in CML cells compared to all normal 
tissues and cells, respectively, while it is considerably 
lower expressed in cells derived from acute myeloid 
leukemia (AML), common acute lymphoblastic leukemia 
(cALL) or chronic lymphocytic leukemia (CLL). 
To test a possible link between LASP1 and the 
BCR‑ABL tyrosine kinase that is the predominant driver 
mutation in CML cells, we subjected BCR‑ABL positive 
(K562, BV173, M07p210) and BCR‑ABL negative 
cell lines for LASP1 expression and pLASP1‑Y171 
phosphorylation, the known phosphorylation site for 
ABL kinase [8]. As shown in Figure 1B, LASP1 is 
expressed in all cancer cell lines tested. However, only 
the leukemia cell lines harboring Ph chromosome with 
constitutively active BCR‑ABL (marked red) show a 
strong phosphorylation of LASP1 at tyrosine‑171. This 
effect is most obvious when comparing the BCR‑ABL 
negative M07e cell line that shows no pLASP1‑Y171 with 
the derivative BCR‑ABL positive cell line M07p210 that 
shows marked LASP1‑Y171 phosphorylation.
LASP1 is phosphorylated at tyrosine 171 in CML 
patients
Using anti‑phosphotyrosine immunoblotting, we 
compared the phosphorylation pattern of LASP1 from 
3 healthy donors with 5 CML patients before and 12 
weeks after commencing treatment with the tyrosine 
kinase inhibitors (TKIs) nilotinib and ponatinib [22, 23]. 
As a control, we probed for CRKL, the most prominent 
BCR‑ABL substrate [7]. The non‑phosphorylated 
CRKL (37 kDa) migrates faster in SDS‑PAGE than its 
phosphorylated form (38 kDa). This is most obvious in 
the BCR‑ABL positive cell line M07p210. As expected, 
CRKL is phosphorylated in CML patients (Figure 2, 
pCRKL band at 38 kDa) while in control blood samples 
from healthy donors, pCRKL was not detected. Likewise, 
we tested for LASP1 phosphorylation by BCR‑ABL 
kinase with a specific antibody against pLASP1‑Y171 
(Supplementary Figure 1), the known ABL kinase 
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Figure 2: LASP1 is phosphorylated in CML patients. Western blot analysis (gradient gel) of LASP1, pLASP1‑Y171 and p/CRKL 
in the leukemia cell line M07p210, in three healthy control donors and in five CML patients before and after TKI treatment. Loading 
M07p210: 10 µg; loading blood samples: 10 µg for LASP1 and β‑actin, 100 µg for pLASP1‑Y171, CRKL and BCR‑ABL WB. Expression 
of ABL is not reliably detectable in CML patients. LASP1 is phosphorylated only in CML patients and in the M07p210 cell line but not 
in controls. In general, CRKL and pLASP1‑Y171 phosphorylation decrease under TKI therapy. Patient 4 shows only minimal cytogenetic 
response to nilotinib treatment (Table 1). 
Figure 1: LASP1 is overexpressed in CML and phosphorylated at Tyr‑171 in leukemia cell lines. (A) Microarray analysis 
of LASP1 (3927_at) in CML compared to normal tissues, normal bone marrow‑derived cells, and myeloid and lymphoblastic leukemias 
(AML, acute myeloid leukemia; cALL, common acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia), Mann-Whitney 
test. (B) Western blot analysis (gradient gel) of phospho/dephospho CRKL (p/CRKL), LASP1 and pLASP1‑Y171 in different cancer 
cell lines (breast cancer: BT‑20, MCF‑7; cervical cancer: HeLa; epidermoid cancer: A‑431; monocytes‑macrophages: U‑937; acute 
myeloid leukemia: MOLM‑13; acute promyelocytic leukemia: NB4; acute monocytic leukemia MV4‑11, THP‑1; erythroleukemia: HEL; 
megakaryoblastic leukemia: M07e; T‑cell leukemia: Jurkat; B‑cell lymphoma: DOHH‑2; acute lymphoblastic leukemia: CCRF‑CEM; 
chronic myeloid leukemia: K562, BV173). Cell lines harboring BCR‑ABL are marked red. β‑actin served as a loading control. 
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phosphorylation site in LASP1. Although present in 
similar protein concentrations, LASP1 is phosphorylated 
at that site only in CML patients and in the M07p210 
cell line but not in controls. After 12 weeks of therapy 
with nilotinib or ponatinib, both, CRKL phosporylation 
and LASP1‑Y171 phosphorylation are impaired and no 
longer detectable by Western blot in CML patients that 
responded to TKI therapy (Figure 2) (for detailed patient 
characteristics, see Table 1). A similar effect is observed in 
M07p210 cells after 24 h treatment with 160 nM nilotinib 
(Figure 2, very left). 
Patient 4 achieved only minimal cytogenetic 
response (minCyR) under nilotinib treatment. 
While LASP1 phoshorylation was absent, CRKL 
phosphorylation, however, was still detectable (Figure 2) 
suggesting different BCR‑ABL substrate specificities for 
both proteins. 
Together, these data suggest that LASP1 is, like 
CRKL, a marker for BCR‑ABL kinase activity in CML. 
LASP1 is a substrate of BCR‑ABL
To further investigate pLASP1‑Y171 
phosphorylation, we used the cell line K562 (derived 
from a patient during blast crisis), as well as wild‑
type M07e and BCR‑ABL transformed M07p210 cell 
lines. Cells were treated with either 100 nM nilotinib at 
various time points or with 10 nM, 40 nM and 160 nM 
of nilotinib for 24h and 48h. DMSO treated cells served 
as control. As seen in Figure 3, LASP1 and CRKL are 
only phosphorylated in the BCR‑ABL expressing cell 
lines K562 (left panel) and M07p210 but not in the BCR‑
ABL negative M07e cells (right panel) Both proteins are 
dephosphorylated in a time‑ and concentration‑dependent 
manner after nilotinib treatment (Figure 3). Similar results 
were obtained with the human CML cell line BV173 (data 
not shown).
To further exclude LASP1 phosphorylation by 
physiologically expressed ABL kinase (see ABL kinase 
Western blots in Figures 3 and 4), we validated these 
experiments with the murine lymphoid cell line Ba/
F3, the BCR‑ABL positive variant of Ba/F3p210 and 
its TKI‑resistant mutant Ba/F3p210T315I. As anticipated 
from the results with M07e and M07p210 (Figure 3), 
only the BCR‑ABL expressing cell lines Ba/F3p210 and 
Ba/F210T315I revealed phosphorylation of LASP1 and 
CRKL (Figure 4). While phosphorylation is reversible 
under nilotinib treatment in Ba/F3p210 cells, the TKI‑
resistant mutant Ba/F3p210T315I cells showed an impaired 
phosphorylation status (Figure 4, right panel), suggesting 
that LASP1 is a direct substrate of BCR‑ABL. 
LASP1 is not localized within the nucleus in CML 
cell lines
A predominant nuclear localization of LASP1 is 
observed in several cancer entities and was reported to 
correlate with worse long‑time survival in breast cancer 
[18]. To test the subcellular LASP1 expression pattern 
in CML, Western blot analyses of cytosolic and nuclear 
fractions from K562, M07e, M07p210, BV173, Ba/F3 
and Ba/F3p210 before and after nilotinib treatment were 
performed.
Loading of the nuclear fractions was tested by 
Western blot analysis for Lamin A/C; GAPDH as a solely 
cytosolic protein served for nuclear purity. As seen from 
Table 1: Patients characteristics
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Sex Male Male Male Female Male
Age at diagnosis, years 23 57 59 54 63
EUTOS score Low risk (42) Low risk (49) Low risk (54) Low risk (14) Low risk (14)
Initial ratio
BCR‑ABL/ABL (%) 50 45 52 62 50
Initial 
WBC (/nl) 112.3 28.4 394.8 55.9 43.1
BCR‑ABL transcript type b2a2 b3a2 b2a2 b3a2 b3a2
Therapy nilotinib nilotinib nilotinib nilotinib ponatinib
3 month 
BCR‑ABL (IS) 0.008 0.013 0.055 20.5 0.263
3 month 
WBC (/nl) 4.2 5.1 6.7 * 13.1 * 13.1
Response at 3 
months MMR MMR MMR * MinCyR * n.d.
MMR, major molecular response; MinCyR, minimal cytogenetic response; IS, international scale; WBC, white blood 
cells; * 6 month; n.d., not detected after 3 months.
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Figure 5A, LASP1 and pLASP1‑Y171 are localized 
exclusively in the cytosol and dephosphorylation of 
LASP1 by nilotinib treatment has no influence on 
subcellular LASP1 localization (shown representative 
for M07e and M07p210 in Figure 5A). These data were 
validated by indirect immunofluorescence of LASP1 in 
K562 and M07p210 cells treated with nilotinib or vehicle 
(shown for M07e and M07p210 in Figure 6).
LASP1 is known to shuttle between the cytosol and 
the nucleus in a phosphorylation dependent manner [24]. 
Phosphorylation of LASP1 by protein kinase A (PKA) 
at serine 146 induces translocation of the protein from 
the cytoplasm to the nucleus by binding to the zonula 
occludens protein 2 (ZO2) [24]. We therefore tested i) for 
the expression of the involved shuttle proteins in CML 
cells and ii) for a potential nuclear translocation of LASP1 
Figure 4: LASP1 and CRKL are phosphorylated by BCR‑ABL‑kinase . Western blot analysis (gradient gel) of BCR‑ABL, 
ABL, LASP1, pLASP1‑Y171 and p/CRKL in Ba/F3 leukemia cell lines. While CRKL and LASP1 phosphorylation is inhibited by nilotinib 
in the BCR‑ABL expressing cell line Ba/F3p210, inhibition failed in the nilotinib resistant BCR‑ABL mutant cell line Ba/F3p210T315I. 
CRKL: (37 kDa); pCRKL: phospho‑CRKL (38 kDa). In the non‑transformed cell line Ba/F3, no BCR‑ABL kinase is present; thus no 
CRKL and LASP1 phosphorylation is observed. β‑actin is shown for loading control.
Figure 3: Phosphorylation of LASP1 and CRKL is inhibited by the tyrosine kinase inhibitor nilotinib. Western blot 
analysis (gradient gel) of BCR‑ABL, ABL, LASP1, pLASP1‑Y171 and p/CRKL in the leukemia cell lines K562 and M07p210 after a 
time‑ and concentration‑dependent treatment with the tyrosine kinase inhibitor nilotinib. CRKL: (37 kDa); pCRKL: phospho‑CRKL (38 
kDa). In the non‑transformed cell line M07e, no BCR‑ABL kinase is present; thus no CRKL and LASP1 phosphorylation is observed. 
β‑actin served as loading control.
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after PKA activation by forskolin. As seen in Figure 5B, 
phosphorylation of LASP1 at Ser‑146 is not inducing any 
translocation of the protein to the nucleus and besides, the 
CML cell lines do not express the LASP1 binding shuttle 
partner ZO2 as do breast cancer cells (Figure 5C). 
pLASP1‑Y171 and CRKL are binding partners
It is well established that tyrosine phosphorylated 
proteins are specifically recognized by SRC Homology 2 
(SH2) domains [25]. To determine the binding preferences 
of different SH2 domains to pLASP1‑Y171, we screened a 
panel of 74 different SH2 domains for preferential binding 
to a LASP1‑Y171 phosphopeptide (Supplementary Figure 
2). The corresponding, non‑phosphorylated peptide served 
as control [26]. SH2 domains of the tyrosine kinases ABL1 
and 2, BLK, FRK, FYN, LCK, LYN, and YES scored 
as top binders of which ABL is already known to bind 
and phosphorylate LASP1 [8, 27]. Among the adaptor 
proteins carrying SH2 domains, CRKL was identified as 
the strongest binder suggesting that CRKL is preferentially 
binding to phosphorylated LASP1 with high affinity.
Figure 6: Immunofluorescence of LASP1 in Mo7e and M07p210 cells. Cells were treated with or without 160 nM nilotinib for 
24 h, fixed, permeabilized and stained for LASP1 (red), actin (green) and merge (yellow). Scale bars 25 µm. No change in cytosolic and 
membranous LASP1 localization is observed.
Figure 5: In CML cells LASP1 is not localized in the nucleus. (A) Western blot analysis (10% gel) of LASP1 and pLASP1‑Y171 
in cytosolic (C) and nuclear (N) fractions of M07e and M07p210 leukemia cells before and after nilotinib treatment. Phosphorylation at 
Tyr‑171 by BCR‑ABL does not influence cytosolic LASP1 localization. (B) Western blot analysis of LASP1 and pLASP1‑S146 in cytosolic 
(C) and nuclear (N) fractions of M07e and M07p210 leukemia cells before and after forskolin stimulation. Phosphorylation of LASP1 by 
PKA does not influence cytosolic LASP1 localization. Purity and loading of the fractions were controlled by Western blot for β‑actin, the 
cytosolic marker GAPDH and the nuclear marker Lamin A/C. (C) Western Blot analysis of LASP1, ZO2 and PKA expression in MDA‑MB 
231 breast cancer cells comapred to K562, M07p210 and M07e leukemia cells. Loading was adjusted to similar ß‑actin levels.
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To verify this predicted interaction, we performed 
far Western blot experiments by overlaying NC‑blotted 
His6‑LASP1 and His6‑pLASP1‑Y171 with GST‑CRKL 
and GST‑pCRKL. For these experiments, His6‑LASP1 
and GST‑CRKL were phosphorylated maximally by active 
recombinant ABL kinase (see Supplementary Figure 3). 
Y171 is the only ABL kinase phosphorylation site in 
LASP1. A second potential tyrosine‑kinase consensus 
sequence at Y186 was excluded earlier by mutational 
analysis [27].
As shown in Figure 7A and in accordance to our 
phosphopeptide binding studies, CRKL and pCRKL, albeit 
to a much lower extent, bind to phosphorylated LASP1 
(pLASP1‑Y171). No binding to non‑phosphorylated 
LASP1 is observed. Equal overlay concentrations were 
confirmed by Western blot (Figure 7B). 
To demonstrate that interaction of CRKL with 
phosphorylated LASP1 is dependent on the SH2 domain 
of CRKL, the arginine residue in the FLVRES‑motif of the 
SH2 domain of CRKL was mutated to lysine. Mutation 
of arginine in the FLVRES‑motif abolishes the binding of 
SH2 domains to phosphorylated tyrosine residues [28]. 
As demonstrated by far Western blot analysis, binding 
of CRKL‑R39K to phosphorylated LASP1 is abrogated 
(Figure 7A) confirming that CRKL primarily interacts 
with phosphorylated LASP1 via its SH2 domain. 
CRKL‑LASP1 binding was further confirmed 
by pulldown and immunoprecipitation assays. For the 
pulldown experiments, purified GST‑LASP1 and GST‑
pLASP1‑Y171 were incubated with K562 cell lysate 
partially pre‑treated for 48 h with nilotinib to inhibit 
BCR‑ABL kinase and to abolish CRKL phosphorylation. 
Western blot analysis for CRKL and pCRKL demonstrated 
only co‑pulldown of dephosphorylated CRKL from the 
nilotinib‑treated K562 cells with GST‑pLASP1‑Y171, 
while no pCRKL binding is observed in the non‑treated 
cell lysate, neither with LASP1 nor with pLASP1‑Y171 
(Figure 7C). The faint visible band binding to 
Figure 7: CRKL binds to phosphorylated LASP1 . (A) Western blot analysis (10% gel) of bound CRKL to LASP1 and phosphorylated 
pLASP1‑Y171 (pLASP). Blotted LASP1 and pLASP1‑Y171 were overlayed with GST (control), GST‑CRKL, phosphorylated GST‑pCRKL 
and mutated GST‑CRKL‑R39K. Binding was detected by GST Western blot. CRKL binds only to phosphorylated pLASP1‑Y171. (B) 
Western blot control of GST‑CRKL concentrations used for the overlay experiment in Figure 6A. (C) Western blot analysis (10% gel) 
of CRKL, pulled‑down with GST‑LASP1 and GST‑pLASP1‑Y171 from K562 homogenate. In the lower Coomassie‑stained part, used 
GST‑beads and K562 homogenate is shown. Phosphorylation of LASP1 at Tyr‑171 results in a faint shift. (D) Western blot analysis 
(10% gel) of CRKL, immunoprecipitated with anti‑CRKL antibody from leukemia cell lines as indicated, and LASP1/pLASP1‑Y171, co‑
immunoprecipitated with CRKL.
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pLASP1‑Y171 in the non‑treated K562 cell homogenate 
is dephospho‑CRKL as confirmed by the band‑shift at 
37 kDa (Figure 7C, upper panel). Similar results were 
obtained with M07p210 ‑/+ nilotinib (data not shown). 
Maximal dephosphorylation of CRKL in nilotinib‑treated 
K562 cells (Figure 7C, middle panel) as well as maximal 
LASP1 phosphorylation (not shown) was controlled by 
Western blot and became also apparent in gel shifts in 
Figure 7C.
Incubation of cell lysate with CRKL specific 
antibody revealed co‑immunoprecipitation of 
pLASP1‑Y171 with CRKL from K562, M07p210 and 
Ba/F3p210 cell homogenate (all active BCR‑ABL) while 
in cell lysates comprising dephosphorylated LASP1 
(Ba/F3 and M07e ‑ no BCR‑ABL or K562/nilotinib 
and M07p210/nilotinib ‑ inactive BCR‑ABL) no co‑
immunoprecipitation of pLASP1‑Y171 is detected (shown 
for K562 and M07p210 in Figure 7D).
In view of the LASP1‑CRKL binding results, 
we also performed immunocytochemistry staining 
experiments in K562 and M07p210 CML cells to test for 
LASP1‑CRKL co‑localization and potential influence on 
protein level before and after dephosphorylation under 
nilotinib treatment. As seen in Supplementary Figure 4, 
independent of their phosphorylation status, both proteins 
are co‑localized at the membrane edges of the cell. 
DISCUSSION
The advent of selective BCR‑ABL tyrosine kinase 
inhibitors revolutionized outcome in CML, and the 
knowledge about the precise molecular mechanisms 
of resistance, signal transduction, and disease biology 
is advancing [29]. Biological markers such as 
BCR‑ABL expression, gene expression profile, CRKL 
phosphorylation or expression of imatinib transporter 
proteins have been shown to be useful to predict response 
to treatment [30]. Notwithstanding, there are still patients 
who fail in achieving therapeutic goals (i.e. major 
molecular or complete cytogenetic response) despite 
continuous TKI therapy. It is thought that leukemia stem 
cells (LSC) (primitive CML progenitor cells) may not be 
strictly addicted to BCR‑ABL and to be able to bypass 
BCR‑ABL signaling via other pathways when treated with 
TK inhibitors [29]. The identification and inhibition of 
these pathways implicated in LSC survival, in combination 
with conventional therapy, is the new therapeutic ambition 
in CML treatment to overcome imatinib resistance and 
eradicate minimal residual disease (MRD) in CML [29].
With LASP1 we identified a novel BCR‑ABL 
substrate in CML. LASP1 is significantly (p < 0.0001) 
overexpressed in CML cells compared to normal tissues, 
bone marrow‑derived cells, and other hematological 
malignancies (Figure 1A). Interestingly, during blast crisis, 
LASP1 mRNA decreases compared to chronic phase as 
shown in a recent microarray analysis [9]. However, no 
data for control mRNA is available for this microarray 
data set [9]. Therefore it remains elusive, whether LASP1 
levels revert to normal during blast crisis or stay up‑
regulated, albeit below chronic phase. Concerning the 
publicly available CML datasets used in the current study 
(Figure 1A), clinical annotation of disease stages were 
either not available or were inconclusive for the majority 
of samples, which precluded robust statistical analysis of 
LASP1 expression in subgroups according to CML phases. 
LASP1 is phosphorylated at Tyr‑171 by BCR‑ABL 
kinase and in turn interacts with the SH2 domain of 
CRKL, the major BCR‑ABL substrate in CML [31]. These 
data suggest that LASP1 may have an important function 
for the biology of this disease. 
Phosphorylation at Ser‑146 and binding to ZO2 
is essential for LASP1 to translocate from the cytosol 
to the nucleus and to transmit extracellular signals [24]. 
This signaling pathway seems to be modified in CML. In 
contrast to cells in a solid tissue or tumor, non‑adherent 
circulating CML cells do not express the indispensable 
LASP1 shuttle partner and tight junction protein ZO2 
(Figure 5C), thus explaining the lack of nuclear LASP1 
in these cells. 
Apart from its involvement in BCR‑ABL signaling, 
LASP1 expression is subsequently induced by sonic 
Hedgehog (SHH) pathway [32] SHH hyperactivation 
correlates with CD34 expression, increases from 
chronic to blast phase [33] and is one out of four major 
pathways that have been implicated in the survival of LSC 
representing a potential therapeutic target [29]. 
An additional fact for the importance of LASP1 in 
CML is the observed binding of LASP1 to chemokine 
receptors (CXCR) 1‑4. CXCR4 mediates the migration 
of hematopoietic cells to the bone marrow and plays a 
key role in the interaction between leukemic and stromal 
cells. BCR‑ABL positive cells show an impaired and 
downregulated expression of CXCR4 [34]. Binding of 
LASP1 to CXCR4 requires phosphorylation of LASP1 at 
Ser‑146 PKA [35]. Whether phosphorylation of LASP1 at 
Tyr‑171 has an effect on CXCR binding has not yet been 
studied.
It is assumed that upon Tyr‑207 phosphorylation 
of CRKL by ABL kinase, an intracellular binding of the 
SH2 domain occurs, preventing the SH2 domain from 
interacting with other phosphorylated ligands [36]. Our 
pulldown and overlay experiments with CRKL and 
pCRKL, in combination with LASP1 and pLASP1, 
confirmed these data. Binding of phosphorylated LASP1 
predominantly occurs with the non‑phosphorylated form 
of CRKL. Both proteins are adaptor proteins co‑localizing 
at the plasma membrane and both are involved in a number 
of biological processes such as cell proliferation, cell 
adhesion, migration, and regulation of gene expression 
[10, 37]. In breast cancer cells, phosphorylation of LASP1 
by ABL kinase occurs during apoptotic processes and is 
associated with the loss of LASP1 localization to focal 
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contacts [8]. However, LASP1 phosphorylation at Tyr‑171 
has also been implicated in integrin mediated SRC 
signalling [27]. Indeed, fibrinogen‑activated SRC kinase 
induced cell spreading, development of lamellipodia and 
translocation of cytosolic LASP1 to focal contacts [27]. A 
similar process has been observed for the association of 
CAS to CRKL [38, 39]. Phosphorylation of CAS by SRC 
promotes binding to CRKL, followed by translocation of 
CRKL to focal contacts and activation of small G‑proteins 
[38, 39]. Therefore we propose that under physiological 
conditions LASP1‑CRKL binding is regulated by SRC 
kinase‑mediated phosphorylation of LASP1 while in 
CML constitutive phosphorylation of CRKL and LASP1 
by BCR‑ABL abrogates the interaction between these 
proteins, which may impair cell adhesion and migration. 
In breast cancer, CRKL and LASP1 were shown to be 
overexpressed and to correlate with tumor growth and 
progression [12, 13, 16, 37, 40]. Similar observations were 
made in glioblastoma. CRKL knockdown in glioblastoma 
cell lines significantly reduced wound healing and 
invasion [41].
In our Western blot analyses of patient‑derived 
blood samples before TKI treatment, we observed 
irregular ratios between β‑actin and LASP1 or CRKL 
levels, respectively (Figure 2). These irregular ratios 
equalizes after nilotinib therapy ‑ most likely due to a 
more physiological blood cell population after successful 
response to TKI treatment. However, β‑actin levels do not 
correspond to white blood cell concentrations. We were 
not able to reliably detect BCR‑ABL and ABL kinase in 
lysates of mature cell compartments from CML patients. 
This is very likely based on the fact that BCR‑ABL and 
ABL are rapidly degraded under our neutral Triton X‑100 
lysis buffer conditions while other proteins are not. The 
degree of degradation depends on hydrolase activity and 
can be prevented by an acidic pH‑value [42]. 
The comparison between lysates derived from cell 
culture, peripheral blood of healthy donors and CML 
patients needs to be interpreted in consideration of their 
composition, i. e. different cell constituents. Due to the 
higher homogeneity of cell lines in culture, cell culture 
experiments reflect more directly the influence of TKI. 
This TKI effect is less apparent with an increasing amount 
of “contaminating” normal cells in patient‑derived blood 
samples (see Table 1, BCR‑ABL expression before and 
after therapy). Accordingly, no LASP1‑phosphorylation 
was detected in patients responding to TKI treatment. 
Results in this cohort reflect the observations made in non‑
CML control samples.
In summary, our data suggest a strong functional link 
between LASP1, CRKL and BCR‑ABL tyrosine kinase, 
therewith explaining and supporting the bioinformatic data 
by Yeung et al [9], who identified LASP1 as a new marker 
for CML progression. The precise biological and clinical 




Publicly available gene expression data of n = 
1322 individual samples were retrieved from the Gene 
Expression Omnibus (GEO) and the Array Express 
platform hosted at the EBI (http://www.ebi.ac.uk/
arrayexpress/). Accession numbers: GSE3526 n = 353 
normal tissues; GSE32719, GSE24739 n = 35 CD34+ 
hematopoietic stem cells (HSCs); GSE2125 n = 45 
macrophages; GSE7158 n = 26 monocytes, GSE31048 
n = 24 B cells, GSE6338 n = 20 T cells; GSE34733, 
GSE17855, GSE35784 n = 404 AML; GSE14671, 
GSE17480, GSE24739, GSE33075, E‑MEXP‑862, 
GSE13159 n = 187 CML; GSE28460 n = 98 B‑precursor 
ALL; GSE39671 n = 130 CLL). All data were generated 
on Affymetrix HG‑U133plus2.0 microarrays. Expression 
data were manually revised for their correct annotations 
and simultaneously normalized by Robust Multichip 
Average (RMA [43] using custom brainarray (v18 
ENTREZG) CDF files yielding one optimized probe‑
set for each gene corresponding to the ENTREZ gene 
ID as described elsewhere [44, 45]. Additionally, gene 
expression data were adjusted for potential batch effects 
using ComBat [46, 47]. Statistical significance levels 
between groups were calculated by Mann‑Whitney test 
using Prism 5 (GraphPad software).
Cell culture conditions
The murine interleukin 3 (IL‑3)‑dependent pre‑B 
lymphoid cell line Ba/F3, the transformed growth‑factor 
independent Ba/F3p210 cells expressing BCR‑ABL, the 
human granulocyte‑macrophage colony‑stimulating factor 
(GM‑CSF)‑dependent megakaryoblastic cell line M07e, 
the human CML cell line BV173, human erythroleukemic 
cells HEL and the human acute myeloid leukemia cell line 
MOLM‑13, were grown in RPMI 1640 supplemented with 
2% L‑Glutamine (Gibco BRL, Wiesbaden, Germany), 
20% heat‑inactivated fetal‑bovine serum (FBS, Gibco 
BRL) without antibiotics. Media for growth of Ba/F3 cells 
and M07e cells were supplemented with 10 ng/mL IL‑3 
and GM‑CSF (Sigma‑Aldrich, Taufkirchen, Germany), 
respectively.
The CML blast crisis cell line K562, the human 
acute monocytic leukemic cell lines MV4‑11 and THP‑1, 
the human T‑cell leukemia cell line Jurkat, the human 
monocyte‑macrophage cell line U‑937, the human 
acute promyelocytic leukemia cell line NB4, the human 
B‑cell lymphoma cell line DOHH‑2, the human acute 
lymphoblastic leukemia CCRF‑CEM the transformed 
growth‑factor independent M07p210 cells expressing 
BCR‑ABL and the TKI‑resistant Ba/F3‑BCR/ABL 
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mutant cell line Ba/F3p210T315I were maintained in RPMI 
1640 (Gibco BRL) with 2% L‑Glutamine, 10% FBS. 
The human breast cancer cell lines MCF‑7 and BT‑20 
as well as the human epidermoid cancer cells A‑431 and 
the human cervical cancer cell line HeLa were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco 
BRL) and 10% FBS. All cell lines were cultivated in a 5% 
CO2 atmosphere at 37°C in a fully humidified incubator. 
The day before each experiment, medium was changed to 
fresh culture media containing 20% FBS. 
Provenience and preparation of human blood 
samples
All procedures were performed with IRB approval 
and complied with relevant national laws, institutional 
guidelines, and the declaration of Helsinki. All donors 
gave written informed consent. Peripheral blood from 
three healthy donors and five patients newly diagnosed to 
suffer from CML in chronic phase was drawn into EDTA 
tubes (Sarstedt, Nuembrecht, Germany). Diagnosis was 
confirmed by blood and bone marrow smears as well as 
multiplex PCR for BCR‑ABL transcripts [48] (see below). 
Patients 1‑4 were treated with 600 mg nilotinib daily (300 
mg every 12h), patient 5 was treated with 45 mg ponatinib 
daily (for detailed patients’ characteristics see Table 
1). Whole blood samples were lysed with five volumes 
of hypotonic erythrocyte lysis buffer (Qiagen, Hilden, 
Germany) from at least 20 ml of peripheral blood. After 
10 min incubation at room temperature (RT) and dual 
centrifugation (472 x g), the plasma‑free leukocytes were 
resuspended in PBS at a concentration of 2 x 107 cells/ml. 
Prepared cells were immediately used for further analysis.
Inhibition of BCR‑ABL
BCR‑ABL activity was blocked using nilotinib 
(Cayman Chemical, Ann Arbor, MI, USA); 10 mM stock 
solution in dimethyl sulfoxide (DMSO) (Sigma‑Aldrich, 
Taufkirchen, Germany) kept at ‑20°C.
Preparation of nuclear and cytosolic cell fractions
For preparation of cell fractions cells were harvested 
and washed twice in PBS. Isolation of nuclei and cytosol 
was carried out using NE‑PER nuclear and cytoplasmic 
extraction reagents (Pierce, Bonn, Germany) following 
the manufacturer’s instructions. Purity of the fractions 
was controlled by probing Western blot membranes for the 
nuclear marker proteins Lamin A/C (sc‑6215, Santa Cruz) 
and the cytoplasmic marker protein GAPDH (sc‑20357, 
Santa Cruz).
Western blot analysis
PBS‑washed cells were lysed on ice at 1 x 107 
cells per 100 μl of 1% Triton X‑100‑based lysis buffer 
containing 20 mM HEPES, 150 mM sodium chloride, 
10 mM EDTA, 2 mM EGTA, 10 mM tetrasodium 
pyrophosphate, 50 mM sodium fluoride, (all Sigma‑
Aldrich). Shortly before lysis 1 mM sodium orthovanadate 
(freshly boiled) and fresh protease inhibitors (Sigma‑
Aldrich) were added. Total protein was quantified using 
the Bradford assay (Biorad, Munich, Germany). Protein 
lysates were subjected to SDS‑PAGE and blotted onto 
PVDF membrane. Equal amounts of protein were analyzed 
by immunoblotting.
The antibody against ABL (#554148) was purchased 
from BD PharmingenTM (Heidelberg, Germany). LASP1 
antibody was described previously [4]. Monoclonal rabbit 
pLASP1‑Y171 specific antibody (1:2000) was generated 
by EB (Supplementary Figure 1). 
Antibody against ZO2 was purchased from New 
England Biolabs (Frankfurt, Germany). Catalytic PKA 
subunit was detected with a specific antiserum kindly 
provided by Dr. G. Schwoch (1:4000; University of 
Göttingen, Germany). 
Western blot analysis of p/CRKL was performed as 
described [7]. CRKL antibody was purchased from Santa 
Cruz (sc‑319, Santa Cruz, Heidelberg, Germany) and 
detects the phosphorylated 38 kDa protein and the non‑
phosphorylated 37 kDa protein by separate band shifts 
in a gradient gel. pCRKL‑Y207 (ab52908) and PY20 
(ab10321) antibodies were purchased from Abcam. Equal 
protein loading was confirmed by documenting β‑actin 
content with the goat polyclonal anti‑β‑actin antibody 
(sc‑1616, Santa Cruz). 
Before overnight incubation with primary 
antibodies, membranes were blocked with 5% dry 
milk (Biorad, Munich, Germany) in TBS‑T for 1h 
at RT. Immunoblots were probed with a secondary 
horseradish peroxidase conjugated antibody purchased 
from Santa Cruz and developed by using the enhanced 
chemiluminescence reagent (GE Healthcare, Freiburg, 
Germany). Chemiluminescence images were taken 
using the Fujifilm LAS‑3000 system (Fuji, Düsseldorf, 
Germany) and quantified by the AIDA Image Analyzer. 
Molecular cloning and expression of CRKL, 
LASP1 and CRKL‑R39K
For PCR amplification of CRKL, gene‑specific 
primers were designed based on the published human 
cDNA sequence (GenBank Access. No. CAG30309.1): 
CGCGTCGACTCATGTCCTCCGCCAGGTTC 
(forward primer with Sall restriction site) and 
CGCGCGGCCGCTCACTCGTTTTCATCTGGGT 
(reverse primer with NotI restriction site). Full length 
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CRKL cDNA was cloned into the Sall and NotI sites of 
pGEX4T‑1 (GE Healthcare) to generate GST‑CRKL 
fusion gene.
To generate GST‑LASP1 fusion gene 
the following oligonucleotides were used: 
AATGGATCCATGAACCCCAACTGCG‑
CCCGGTGCGGCAAG (sense, with BamHI restriction 
site) and CGGGAATTCTCAGATGGCCTCCACGTA 
GTTGGCCGGCA (antisense, with EcoRI restriction site).
For generating His6‑tagged 
LASP1 we used the oligonucleotides 
CGCCATATGAACCCCAACTGCGCCCGG 
(forward primer with NdeI restriction site) and 
CGCCTCGAGTCAGATGGCCTCCACGTAGT (reverse 
primer with XhoI restriction site). In order to get the 
His6‑tagged LASP1, full length cDNA (GenBank Access. 
No. X82456) was cloned into the NdeI and XhoI sites of 
pET‑28b vector (Novagen/Merck Millipore).
To exchange arginine for lysine at 
position 39 of CRKL protein, amino acid 
sequence appropriate primers were designed: 
CACGGTATGTTCCTCGTCAAGGATTCTTC 
CACCTGCCCT (sense) and 
AGGGCAGGTGGAAGAATCCTTGACGAGG 
AACATACCGTG (antisense) (www. stratagene.com).
The recombinant vector pGEX4T‑1‑CRKL served as 
template for mutagenesis‑PCR. The PCR was performed 
using QuickChange Site‑directed Mutagenesis Kit 
(Agilent Technologies, Böblingen, Germany) according 
to supplier instructions.
All constructs were verified by DNA sequence 
analysis. All primers were synthesized by Eurofins MWG 
Synthesis GmbH (Ebersberg, Germany).
RNA extraction, reverse transcription and 
quantitative real‑time polymerase chain reaction
Total leukocyte RNA was extracted from at least 2 x 
107 peripheral leukocytes using Trizol reagent (Invitrogen, 
Karlsruhe, Germany) according to the manufacturer’s 
instructions after lysis of red blood cells. Messenger 
RNA was reversely transcribed into complementary DNA 
(cDNA) using random hexamers as described before 
[49]. The assessment of BCR‑ABL transcript level was 
performed using qRT‑PCR as previously described [50]. 
BCR‑ABL transcript levels were expressed as a ratio 
BCR‑ABL/ABL according to the International Scale, IS 
[51]. 
Protein expression and purification
CRKL, CRKL‑R39K and LASP1 were expressed as 
GST‑fusion‑proteins in BL21DE3cells (NEB, Frankfurt 
am Main, Germany). After lysis (50 mM Tris, 1 mM 
EDTA, 100 mM NaCl, 0.1% Triton X‑100, pH 8.0 and 
protease inhibitor cocktail) and sonication, fusion proteins 
were affinity‑purified using gluthatione‑sepharose 4B (GE 
Healthcare, Freiburg, Germany) and eluted with 60 mM 
glutathione (Roche, Mannheim, Germany).
For His6‑tagged LASP1, the recombinant 
pET28b‑LASP1 vector was transformed into BL21DE3 
E. coli. Bacteria were lysed (50 mM Tris, 0.6 mM EDTA, 
300 mM NaCl, 0.1% Triton X‑100, pH 8.0 and protease 
inhibitor cocktail), sonicated and His6‑LASP1 was 
affinity‑purified using HisTrap HP affinity columns (GE 
Healthcare) following the instructions of the supplier.
Protein levels were up‑concentrated using 
Centricon® Centrifugal Filter Devices YM‑10 / YM‑30 
(Amicon, Merck Millipore). Proteins are stable for at least 
6 weeks at 4°C.
Phosphorylation of CRKL and LASP1
LASP1 and CRKL were phosphorylated by 
recombinant active ABL kinase (BPS Bioscience, 
San Diego, CA, USA) according to the suppliers 
recommendations at 30°C in phosphorylation buffer (5 
mM Tris, 1 mM MgCl2, 0.1 mM DTT and 100 µM ATP). 
For maximal phosphorylation (Supplementary Figure 3), 
LASP1 had to be incubated with ABL kinase for at least 
2h and CRKL for at least 4h (overnight). To block kinase 
activity in the subsequent experiments, 20fold excess of 
nilotinib (Cayman Chemical, Ann Arbor, MI, USA) related 
to ABL kinase concentration was added (Supplementary 
Figure 3). 
Phosphorylation was visualized by Western blot 
analysis with phosphotyrosine antibody PY20 (1:1000), 
pCRKL (1:5000) or monoclonal rabbit pLASP1‑Y171 
specific antibody generated in‑house (Supplementary 
Figure 1) followed by secondary horseradish peroxidase‑
coupled goat‑anti‑mouse or goat‑anti‑rabbit IgG antibody 
(1:5000) (Biorad, Munich, Germany).
Overlay (Far western blot)
0.2 µg of His6‑LASP1 and His6‑LASP1 
phosphorylated by ABL kinase were blotted on 
nitrocellulose by semi‑dry technique. To minimize 
background binding, membranes were incubated with 
5% dry milk in TBS‑T for 2h at RT. Membranes were 
overlaid overnight at 4°C with 1 µg GST‑tagged proteins. 
After three washing steps with TBS‑T, membranes 
were incubated with GST‑antibody (ImmunoGlobe, 
Himmelstadt, Germany) 1:1000 in 5% dry milk in TBS‑T 
followed by secondary horseradish peroxidase‑coupled 
goat‑anti‑rabbit IgG antibody (1:5000) (Biorad) and 
enhanced chemiluminescence reagent (GE Healthcare).
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Immunoprecipitation
For immunoprecipitation 1 x 107 cells were 
lysed as described above in 500 μl of lysis buffer. After 
centrifugation (14000 x g for 15 min) the supernatants 
were discharged. Immunoprecipitation was performed 
by incubating of 500 μl supernatant with 2 µg of the p/
CRKL antibody for 2 h at 4°C followed by incubation with 
protein A‑Sepharose (50 µl) under continuous rotation 
over night at 4°C. The immunocomplex was washed three 
times with ice‑cold lysis buffer, once with 0.5 M LiCl and 
again with lysis buffer and prepared for SDS–PAGE as 
described above.
Pulldown experiments
Cells were lysed with 1% Triton X‑100‑based lysis 
buffer described above. After centrifugation (14000 x g for 
15 min) the supernatants were incubated for 2 h with 50 
µl GST control beads or GST‑tagged proteins. Beads were 
washed three times with PBS and analyzed by SDS–PAGE 
and Western blot as described above
Phosphopeptide binding assay
LASP1 peptides (biotin‑Ahx‑
GDGDGGGDDPVpYQQPQQ) corresponding to aa 
position 169‑176 of human LASP1 were synthezised by 
Biosynthan (Berlin, Germany). The peptides carried a 
biotin and an aminohexane (Ahx) spacer at the N‑terminus 
followed by a GDGDGGGDD spacer to improve binding. 
500 fm of peptide/well were immobilized in 0.1% BSA/
PBS to streptavidin coated 96‑well microtiter plates 
(Roche, Mannheim, Germany) for 1h at RT. After washing 
with 0.1% TBS‑T, free streptavidin binding sites were 
quenched with 1 mM biotin for 30 min at RT and plates 
were blocked overnight at 4°C in 5% blocking solution 
(Roche) in the presence of 100 µM sodium orthovanadate. 
After washing (3 times in 0.1% TBS‑T), peptides were 
incubated in a final volume of 200 µl for 1h at RT with 50 
ng/well of SH2 domain precomplexed with streptavidin‑
HRP (Pierce) as previously described [52]. Plates were 
washed (8 times) with 200 µl 0.1% TBS‑T, 0.1% of 
ABTS (Roche) was added, plates were incubated for 10 
to 30 min at 37°C and OD was measured on a microplate 
reader at 405 nm. All binding reactions were performed 
in duplicate.
Immunofluorescence and confocal laser scanning 
microscopy
For confocal laser scanning microscopy (CLSM) 3,5 
x 104 cells were fixed by adding 10% formalin directly 
into the culture medium, for a final concentration of 
5% which is equivalent to 2% paraformaldehyde. After 
10 min incubation at 4°C, cells were centrifuged and 
washed twice with cold PBS at 1000 x g for 2 minutes at 
4°C. Samples were then transferred into a centrifugation 
chamber with releasable fixing plates and centrifuged 
for 10 min at 140 x g and RT to generate cytospins. 
Sections were rinsed in 100% methanol for 5 min at ‑20 
C to perforate cell membranes, air dried, and incubated 
in 5% BSA in 1 x TBS‑T (7.4 mM Tris base; 43.5 mM 
Tris HCl; 150 mM sodium chloride; 0.1% Tween 20) for 5 
min at RT. Subsequently, slices were stained with affinity‑
purified rabbit polyclonal LASP1 antibody (diluted 1 
µg/ml) [19], mouse monoclonal CRKL antibody (1:200; 
Merck Millipore, Darmstadt, Germany) and Oregon 
green phalloidin antibody (1:50; Invitrogen, Karlsruhe, 
Germany) followed by secondary Cy3‑labeled anti‑
rabbit antibody (1:500, Dianova, Hamburg, Germany). 
Fluorescence recordings were performed using a confocal 
laser scanning microscope (LSM 510; Carl Zeiss, Jena, 
Germany) or an inverted microscope (Axiovert 135; Carl 
Zeiss). An Axiovison software tool (Carl Zeiss) was used 
for quantitative analysis. 
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